Mucosal high-risk (HR) human papillomaviruses (HPV) cause a subset of head and neck cancers (HNC). The HPV-attributable fraction of HNC varies substantially between countries. Although HNC has a very high incidence in the Indian subcontinent, information on the contribution of HPV infection is limited. Here, we evaluated the HPV-attributable fraction in HNC (N 5 364) collected in a central region of India. HNC from three different anatomical subsites were included, namely, oral cavity (n 5 252), oropharynx (n 5 53) and hypopharynx/larynx (n 5 59). In this retrospective study, HPV-driven HNC were defined by presence of both viral DNA and RNA.
the cases; however, only 2.7% were positive for both HPV DNA and RNA. The highest percentage of HPV DNA/RNA double positivity was found in oropharynx (9.4%), followed by larynx (1.7%) and oral cavity (1.6%) (p 5 0.02). More than half of HPV DNA/RNA-positive cases were p16 INK4a -negative, while a considerable number of HPV RNA-negative cases were p16 INK4a -positive (17.9%). HPV16 was the major type associated with HNC (60.0%), although cases positive for HPV18, 35 and 56 were also detected. Our data indicate that the proportion and types of mucosal HR-HPV associated with HNC in this central Indian region differ from those in other (developed) parts of the world. This may be explained by differences in smoking and/or sexual behaviour compared with North America and northern Europe. Moreover, we show that p16 INK4a staining appeared not to be a good surrogate marker of HPV transformation in the Indian HNC cases.
With approximately 700,000 incident cases, head and neck cancer (HNC) is the sixth most common malignancy worldwide. Around 380,000 deaths per year are due to HNC. 1, 2 Alcohol consumption, smoking, poor oral hygiene and genetic features are the key risk factors for HNC development. 3 Over the past two decades, it has become clear that a subset of HNC is associated with certain mucosal high-risk (HR) HPV types, [3] [4] [5] [6] [7] specifically HPV16 (86-95%), while the contribution of the remaining HPV types is unclear. 8 Although the overall incidence of HNC is decreasing in developed countries due to increasing awareness of tobacco and alcohol as risk factors for human carcinogenesis, the proportion of HPV-positive oropharyngeal cancers among HNC has steadily increased in the USA and northern Europe. 3, [9] [10] [11] However, epidemiological studies highlighted that the fraction of oropharyngeal cancer associated with HR-HPV types can vary substantially in different countries. 3, 12 The Indian subcontinent has the highest HNC incidence (6.1/100,000 women and 20.9/100,000 men) 1 in the world and accounts for one-third of the world HNC burden. In this geographical area, HNC is the first and third most common malignancy in men and women, respectively. 1 Many etiological factors are involved in HNC development in the Indian population, including alcohol and smoking. The habit of chewing betel quid often mixed with tobacco is widespread in South Asia, and also plays a key role in HNC development. 13 Although age-standardized rates of cervical cancer are among the highest in India 1,2 (22.0/100,000), highlighting the importance of HPV infections in this population, limited information on HPV-associated HNC exists. [14] [15] [16] [17] [18] [19] [20] [21] The studies published thus far have been based on a limited number of cases. In addition, HPV positivity was ascertained by PCRbased assays alone. However, HPV DNA detection alone is insufficient proof for viral causality. [22] [23] [24] [25] Additional markers, such as viral RNA, antibodies against the viral oncoproteins and p16
INK4a expression as a surrogate for HPV-induced transformation, allow a more precise classification of HNC. 8, 24, [26] [27] [28] [29] Therefore, additional studies applying appropriate molecular methods are required to precisely establish the HR-HPV-attributable fraction for HNC in India.
In the context of a recent European and Indian case study (HPV-AHEAD, http://hpv-ahead.iarc.fr), we have collected approximately 3,000 formalin-fixed paraffin-embedded (FFPE) HNC tissues in six different urban (n 5 3) and rural (n 5 3) hospitals in India, with the aim to determine the HPV-attributed fraction using several laboratory assays. To identify HR-HPV-attributable tumours, a stringent protocol was applied which included the detection of both viral DNA and RNA, as well as p16
INK4a staining. In this article, we describe the first results of a comprehensive histological and molecular assessment of a large number of archived HNC specimens from one rural hospital in central India, using the above-mentioned stringent protocol which includes the detection of viral DNA and RNA as well as p16
INK4a staining.
Materials and Methods

Specimen collection
We 
Preparation of the tissue sections
FFPE-tissues were in part processed at the International Agency for Research on Cancer, Lyon, France and at the Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram, Kerala, India, following the HPV-AHEAD sectioning protocol. Briefly, depending on the size of the tissue 10-31 sections (S) were generated from each FFPE block. The first (S1) and the last (S10 or S31) sections were haematoxylin/ eosin stained for histology and used to check for the presence of tumour. S2 and S9 were generated for p16 INK4a immunohistochemical staining, while sections 3-5 (10 l) and 6-8 (10 l) were used for the extraction of RNA and DNA, respectively. To minimize the risk of cross-contamination during sectioning, a new blade was used for each FFPE block and the microtome was extensively cleaned after each block with ethanol 70% and DNA Away (Dutscher, Brumath, France). In addition, to monitor possible DNA contamination, after 10 tumour tissue blocks, sections were generated from an empty paraffin block and all were included in the DNA analyses.
Histological analysis
All sections were analysed by the HPV-AHEAD pathology review panel that includes three European (JPB, BLR, FM) and three Indian (TS, RVK, NG) pathologists. An online pathology evaluation form generated by the six pathologists was used. Each pathologist analysed tissues from approximately 80 patients. All sections were re-analysed by a second panel pathologist. Only FFPE blocks where the first and last haematoxylin/eosin sections reflected tumour tissue were included in the study.
HPV DNA genotyping
For DNA extraction, three consecutive sections (S6-8) of each block were pooled and incubated in digestion buffer (10 mM Tris/HCl pH 7.4, proteinase K 0.5 mg/ml and Tween 20 0.4%) at 378C overnight. 20 Water samples were included to monitor possible contaminations during the preparation of DNA. HPV typing was detected by a type-specific multiplex genotyping (TS-MPG) assay, which combines multiplex PCR and bead-based Luminex Technology (Luminex Corporation, Austin, TX), as previously described. 30 , and 117 bp for b-globin, were applied. After PCR amplification, 10 ml of each reaction mixture was analysed by multiplex HPV genotyping (MPG) using Luminex technology (Luminex Corporation, Austin, TX) as described previously. 31 Genotyping controls and DNA preparation were blindly analysed and no sign of contamination of negative controls was detected during the laboratory work. All HPV DNA-positive FFPE specimens and a random subgroup of approximately 10% of HPV DNA-negative specimens were further analysed for the presence of HPV E6*I mRNA and overexpression of the cell cycle inhibitor p16 INK4a that is considered a surrogate marker for HPV infection. The 10% of HPV DNA-negative cases were selected randomly and blindly (roughly 1 of every 10 HPV DNA-negative cases), while the study was still anonymized.
HPV RNA analysis
Total RNA was purified from 3 pooled consecutive sections of the same tissue block using the PureLink FFPE Total RNA Isolation Kit (Invitrogen, Carlsbad, CA) as described previously. 32 Extracted RNA was eluted in 50 ml of RNase-free water and stored at 2808C until further use. A DNase I treatment was carried out on the total RNA, following the manufacturer's instructions (Qiagen, Hilden, Germany). RT-PCR was carried out using the QuantiTect Virus Kit (Qiagen), in a total volume of 25 ml containing 5 ml of 53 QuantiTect Virus Mastermix, 0.25 ml of 1003 QuantiTect Virus RT Mix, 0.4 mM of each primer and 1 ml RNA input as described previously. 32 Reverse transcription was carried out at 508C for 20 min, directly followed by an initial PCR activation step at 958C for 5 min in a PCR thermocycler (Mastercycler, Eppendorf AG, Hamburg, Germany). cDNA was amplified in 40 cycles, each including a 15 s denaturation
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step at 958C and a 45 s combined annealing/extension step at 608C. The HPV type-specific E6*I mRNA assays developed for 20 HR/pHR-HPV types 32 were applied for detection of viral transcripts. These assays amplify 65-75 bp HPV and 81 bp ubiquitin C (ubC) cDNA. Analytical sensitivity of each assay is 10 to 100 copies per reaction for 19 HPV types and for ubC and 10,000 copies for HPV70. 22 All HPV DNApositive specimens and a randomly selected 10% of HPV DNA-negative specimens were analysed for the presence of (i) HPV16 E6*I mRNA and (ii) ubC mRNA as a cellular mRNA positive control. Tissues positive for DNA of a non-HPV16 type were additionally analysed for E6*I mRNA of this type. Specimens that were HPV E6*I and/or ubC mRNA-positive (RNA1) in RNA analysis were considered RNA valid.
p16
INK4a immunohistochemistry
For p16
INK4a immunohistochemistry, a dual-immunostaining protocol for the simultaneous immunostaining for both p16
INK4a and Ki-67 biomarkers has been applied using the CINtec PLUS kit (Roche mtm laboratories AG, Mannheim, Germany). This dual-staining approach was used to facilitate the identification and assessment of the area of the tissue section comprising the cancer tissue. Slide S2 was simultaneously stained for p16
INK4a and Ki-67 using the CINtec PLUS dual-stain kit (Roche mtm laboratories). At an early phase of the HPV-AHEAD study, we performed a comparative analysis on 185 cases where in addition to slide S2 stained with the p16
INK4a /Ki-67 dual-stain kit, slide S9 of each cases was single-stained only for p16
INK4a using the CINtec Histology p16
INK4a Histology Kit (Roche mtm laboratories), which has been developed and optimized for use on tissue sections prepared from formalin-fixed, paraffin-embedded specimens. The comparison showed concordant p16
INK4a staining results in >98% of the cases, indicating that the dual-stain protocol provides comparable p16
INK4a staining results as the singlestain protocol, which was optimized for tissue sections. Therefore, we continued the study using the p16 INK4a /Ki-67 dual-stain protocol using the CINtec PLUS kit and slide S2 for the whole study. A continuous, diffuse staining for p16
INK4a within the cancer area of the tissue sections was considered as positive, while a focal staining or no staining was considered negative. IHC slides were analysed without knowledge of any other clinical information (including HPV DNA and RNA status) by RR, DH and three members of the HPV-AHEAD pathology review panel (JPB, FM and BL). Each staining has been reviewed by at least one researcher and one pathologist. Discrepant cases have been re-checked by a pathologist and final classification of the staining was based on the major consensus of the working group.
Statistical analysis
The primary outcome was HPV-related tumours defined as being HR-HPV DNA-and RNA-positive for the corresponding type, with cases that were HPV DNA-or RNA-negative considered HPV-unrelated. The prevalence of HPV in oropharyngeal, oral cavity and laryngeal SCC cancer patients was compared by subsite and HPV type using the Fisher's exact test. ANOVA test was used to compare mean age by anatomical site The proportion of cancers caused by HPV and 95% confidence interval for the estimate are reported. The concordance between HPV DNA detection, RNA positivity and p16 expression levels was examined by percentage of agreement, kappa statistic (and Prevalence-Adjusted BiasAdjusted Kappa (PABAK) 5 2*observed agreement-1) and McNemar's test p values. PABAK statistic is a correction of the concordance used when the agreement was high but the kappa was low. All statistical analyses were performed using STATA statistical software, version 13.1 (StataCorp, College Station, TX), and all reported P values are two sided. Statistical significance was set at p <0.05.
Results
Of the 484 patients, two were excluded due to incomplete clinical information and 103 were also excluded as they were diagnosed with cancers of salivary glands (n 5 4) and sinus (n 5 27) or the tissue block did not contain cancer tissue (n 5 72). Of the remaining 379 patients processed for HPV genotyping, 15 extracted DNAs resulted to have poor quality as evidenced by negative ß-globin PCR assay results. Table 1 shows the available information of the final study group of 364 HNC patients, that includes 252 oral cancers, 53 oropharynx and 59 larynx cancers (including hypopharynx, n 5 18). Mean age at diagnosis was 53.6 years (standard deviation (SD)512.7), mainly from male (72.3%) patients diagnosed with conventional squamous cell carcinoma (SCC) (61.0%) between mid-2005 and December 2011. Differences in age, sex and histological diagnosis were observed between HNC subsites: cases of oropharyngeal cancer occurred in older patients, affected a higher proportion of men and had less keratinizing and more basaloid histologies than did cases at the other sites. Table 2 shows the HPV DNA, RNA, and  p16 INK4a detection in HNC cases. Of the 364 HNC specimens, 50 (13.7%) contained HPV DNA. HPV16 was the most prevalent type, being present in 36 of the 50 HPV DNA-positive tumours (72.0%), followed by HPV31 (6/50, 12.0%), HPV18 (4/50, 8.0%), HPV35 (2/50, 4.0%) and HPV56 (2/50, 4.0%). No tumour contained DNA from LR-HPV types or from multiple HR-HPV types. Oropharynx showed the highest HR-HPV DNA prevalence (10/53, 18.9%), followed by larynx (10/59, 16.9%) and oral cavity (30/252, 11.9%).
The percentage of HPV-related HNC was 2.7% (10/364) for HPV DNA/RNA positivity and dropped to 1.1% (4/364) when all three markers, that is, HPV DNA/RNA and p16
INK4a were considered. The stratification for HNC subsites and different HPV types is shown in Table 2 . The highest percentage of HPV DNA/RNA positivity was found in the oropharynx (five out of 53 HPV DNA-positive cases, 9.4%), comprising three for HPV16, one for HPV35 and one for HPV56. A small percentage of oral cavity (4/252, 1.6%) and laryngeal cancers (1/59, 1.7%) resulted test-positive for both DNA and RNA for HPV16, 18 or 35. Those differences between subsites were statistically significant (p 5 0.02). We observed that HPV16 and the group of the other mucosal HR-HPV types were similarly represented in oral cavity, being two positive for HPV16 DNA/RNA and two positive for HPV18 or 35 DNA/RNA. The number of HNC cases positive for HPV DNA/RNA and p16
INK4a was low (n 5 4).
These cases included three oropharyngeal (HPV16 and HPV56) and one laryngeal (HPV16) cancers (Table 2) . In the concordance analysis including the results for the random sample of 38 HPV DNA-negative cases, we observed a slight concordance between HPV16 DNA with RNA (kappa: 0.10; PABAK 5 0.23; p < 0.01), further improved for non-HPV16 types (kappa: 0.23; PABAK 5 0.64; p 5 0.03) and slight concordance between HPV DNA status with p16 (Table 3 ). In addition, 11 out of 40 (27.5%) HNC cases that were HPV DNA-positive, but RNA-negative, were tested positive by p16 INK4a IHC. Proportional to the number of oral cancers analysed, the majority of these p16 INK4a -positive HNC were from this anatomical site. Moreover, six out of 10 HPV DNA/RNA-positive cases (60.0%) were negative for p16
INK4a
, and 14 out of 78 HPV RNA-negative cases (17.9%) were p16
-positive (Table 3) . To further evaluate the significance of HPV DNA positivity in HNC specimens, we retrieved multiple FFPE tissue blocks from five HPV DNA-positive and HPV RNA-negative patients, namely, one patient with two blocks, three patients with three blocks and one patient with four blocks. The histological analysis confirmed that all FFPE blocks contained cancer tissue. In all cases, we detected HPV DNA only in one specimen for each patient (data not shown).
Discussion
It is now well demonstrated that mucosal HR-HPV types, mainly HPV16, are causally involved in a significant proportion of oropharyngeal cancers and in a much lower extent in a subset of other HNC. However, the contribution of HR-HPV to HNC appears to be the subject to geographical variability. 6 Although HNC incidence is very high in India, only a limited number of studies have evaluated the contribution of HPV infection. [14] [15] [16] [17] [18] [19] [20] [21] 33, 34 In these studies, the proportion of HPV-positive cases was established only by detecting viral 
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Gheit et al. Table 2 . HPV DNA, RNA, and p16INK4a positivity in HNC subsites by HPV status DNA using PCR-based assays, and HPV positivity of HNC cases substantially varied between studies, ranging from 15% to 70%. [14] [15] [16] [17] [18] [19] [20] [21] Several independent studies have highlighted that PCR-based assays for the detection of HPV DNA are not sufficiently accurate to establish the viral causality. [22] [23] [24] [25] Due to their high sensitivity, these assays detect traces of viral DNA present in the oral cavity, which may not be necessarily directly linked to the carcinogenic process. A recent Indian study also determined the presence of HPV RNA by in situ hybridization. 35 A very low prevalence of HPVassociated HNC (1.8%, 8/427) was detected. This lower percentage of HPV RNA-positive cases in comparison with our study may be explained by the different sensitivities of the RNA detection assays used in the two studies.
Here, we have evaluated the contribution of HPV to HNC development in a central Indian region by detecting HPV DNA and RNA, as well as by determining the positivity for p16 INK4a . Fourteen percent of HNC contained HR-HPV DNA, but only 3% were positive for both HPV DNA and RNA. Thus, the HNC fraction attributable to transforming HPV infections in this Indian region appeared to be considerably lower compared to various other geographical regions worldwide. 6 In agreement with previous studies in other countries and continents, the highest percentage of HPV DNA and RNA double positivity was found in the oropharynx (9.4%). Regarding the other anatomical sites, only a small fraction of oral cavity and laryngeal cancers were double-positive for HPV DNA and RNA (1.6% and 1.7%, 
